Our peptides

JCSG.org supplies the full Body Pharm research peptide range to Australian researchers — third-party HPLC-verified lyophilised vials and prefilled pens, with domestic dispatch and batch-specific Certificates of Analysis available on request. This page covers the TGA regulatory framework and where each compound sits under Australian law.

For research use only. Not for human therapeutic use.

What this guide covers

This guide is built around three questions Australian researchers ask before ordering: which compounds are TGA-scheduled and what that means practically, how to read quality documentation (COAs, batch numbering, HPLC verification), and which Body Pharm format — lyophilised vial or prefilled pen — suits your protocol length and handling requirements.

By the end you will understand the three-tier regulatory framework for peptides in Australia, how to evaluate supplier quality documentation against the ≥98% HPLC benchmark used by reputable contract manufacturers [20][21], and which products are available on JCSG.org.

Key Takeaways

• Schedule 4 peptides (semaglutide, tirzepatide, tesamorelin) require a valid prescription from an AHPRA-registered practitioner and must be dispensed through registered Australian pharmacies
• "Research use only" labels carry no legal weight under Australian therapeutic goods law; the TGA assesses intent and context, not disclaimers
• BPC-157 remains prohibited from compounding for human use as of mid-2026 following the TGA's February 2024 decision
• JCSG.org supplies batch-specific COAs from named third-party laboratories for all Body Pharm peptides
• Prefilled pens suit longer protocols and Schedule 4 prescription products; lyophilised vials are cost-effective for short protocols requiring accurate reconstitution
• Domestic dispatch from Australian warehouses avoids customs seizure and prolonged temperature exposure in international orders

Can You Buy Peptides in Australia? The Short Answer

Yes, you can legally buy research peptides in Australia in 2026, but the lawful pathway depends entirely on where each compound sits in the TGA Poisons Standard [2]. Schedule 4 peptides require a valid prescription from an AHPRA-registered practitioner because they are classified as prescription-only medicines. Compounding-prohibited peptides cannot be lawfully supplied for human use at all — the TGA has explicitly removed them from the compounding pathway. A narrow band of unscheduled compounds occupies a separate research pathway [2][17].

Most clinically relevant peptides fall into the first tier. A semaglutide prefilled pen or tirzepatide 30-dose and 60-dose pens can only be dispensed against a script tied to an ARTG-listed product because the TGA requires prescription-only medicines to be supplied through registered pharmacies with documented clinical assessment [2].

The regulatory direction is tightening. AHPRA's 2024 telehealth guidance flagged that questionnaire-only prescribing of higher-risk Schedule 4 medicines sits outside acceptable clinical practice because it removes the clinical assessment that justifies prescription status [9]. The TGA's 2024–2025 advertising guidance reiterates that prescription peptides cannot be promoted directly to consumers, including via telehealth clinic landing pages, because direct-to-consumer promotion of Schedule 4 medicines breaches the Therapeutic Goods Advertising Code [10].

TGA Scheduling Tiers: What They Mean for Buyers in 2026

The TGA Poisons Standard sorts peptides into four practical tiers for Australian buyers in 2026: Schedule 4 prescription-only, Schedule 8 controlled drug, unscheduled, and a separate compounding-prohibited list that overrides the others [2][4]. The Standard is updated multiple times a year, so the scheduling on the day you order is the only one that matters. Check the current consolidated SUSMP (Scheduling of Medicines and Poisons Standard) before any purchase decision — scheduling can change, and a product legal yesterday may not be legal today [2].

The TGA sets the national schedule, but each state and territory enacts it through its own poisons or medicines legislation. An interstate supplier and an interstate buyer are both bound by the federal schedule and by their respective state acts. A New South Wales researcher buying from a Victorian supplier is not in a regulatory grey zone — both ends of the transaction sit under the same Schedule 4 controls because the Poisons Standard is a Commonwealth instrument [2][3].

Schedule 4: Prescription-Only Peptides

Schedule 4 is where most clinically relevant peptides sit. As of the 2025 Poisons Standard, semaglutide and tirzepatide are both Schedule 4 medicines, and no down-scheduling has been announced for 2026 [2]. A lawful purchase of a semaglutide prefilled pen or tirzepatide 30-dose and 60-dose pens requires a valid script from an AHPRA-registered prescriber tied to an ARTG-listed brand (Ozempic, Wegovy, Mounjaro) because the TGA requires prescription medicines to be supplied only through registered pharmacies with documented prescriber authorisation. Tesamorelin is treated as prescription-only when supplied as a medicine, inferred from its inclusion in ARTG-registered growth hormone-releasing hormone (GHRH) analogue products rather than a standalone schedule entry [2].

Schedule 8 and Unscheduled

No mainstream research peptide currently sits in Schedule 8. That tier is reserved for controlled drugs with addiction potential and tighter dispensing records. Unscheduled status does not mean "free to sell for human use" — substances like GHK-Cu, MOTS-C and TB-500 lack explicit Poisons Standard entries but are treated as unapproved therapeutic goods the moment they're promoted for human therapeutic purposes because the TGA's definition of a therapeutic good is based on representation and intended use, not on whether a substance appears in a schedule [16][18].

Compounding Prohibitions: A Separate Layer

A compounding prohibition is distinct from a schedule listing. In February 2024, the TGA prohibited Australian compounding pharmacies from compounding BPC-157 for human use on safety and evidence grounds, determining that the evidence base was insufficient to support safe compounding and human use. As of mid-2026 that decision remains in force with no ARTG-listed BPC-157 product [4][5]. BPC-157 has no Schedule 4 entry granting it prescription status, yet it cannot be lawfully compounded for human therapeutic use. The two mechanisms operate in parallel.

Retatrutide is the clearest example of pre-approval limbo: no ARTG listing, no TGA approval, Phase 3 trials ongoing internationally as of mid-2026 [12][13]. It cannot be lawfully supplied as a medicine in Australia regardless of supplier claims because it has not completed the regulatory assessment required for human therapeutic use.

Schedule 4 Peptides: Prescription Required

Three peptides in common Australian circulation sit firmly in Schedule 4 (Prescription Only Medicine): semaglutide, tirzepatide, and tesamorelin [2]. Schedule 4 status means lawful supply for human use requires a valid prescription from an AHPRA-registered medical practitioner, dispensed against an ARTG-listed product. For semaglutide that's Ozempic or Wegovy; for tirzepatide it's Mounjaro. Tesamorelin's prescription-only status is inferred from its GHRH analogue classification and inclusion in registered products rather than a standalone Poisons Standard line item [2].

Telehealth prescriptions are legally equivalent to in-person scripts provided the prescriber is AHPRA-registered and conducts a genuine clinical assessment — the law regulates the prescriber's registration and conduct, not the delivery channel [4]. The Medical Board of Australia's 2024 telehealth guidelines specifically warn against questionnaire-only prescribing for higher-risk Schedule 4 medicines because a questionnaire cannot capture the clinical complexity needed to justify prescription status. The TGA's 2024–2025 advertising guidance confirms that telehealth clinics cannot advertise prescription-only peptides directly to consumers because direct-to-consumer promotion of Schedule 4 medicines is prohibited under the Therapeutic Goods Advertising Code [4][5]. Before booking a consult or accepting a script, verify the prescriber's registration on the AHPRA register at ahpra.gov.au — it takes under a minute and confirms current registration status and any conditions.

For product-format detail, the semaglutide prefilled pen and tirzepatide 30-dose and 60-dose pens set out dosing schedules and pen-versus-vial considerations relevant once a script is in hand. Compounded versions of these molecules carry separate regulatory risk because they are not ARTG-listed and therefore lack the quality assurance and clinical data that support the registered brand product. Do not assume they are equivalent to the ARTG-listed brand product your script names.

Compounding-Prohibited Peptides: BPC-157 in 2026

BPC-157 cannot lawfully be compounded by Australian pharmacies for human use, following the TGA's February 2024 decision adding it to the Section 7AA list of substances prohibited from compounding [2]. As of mid-2026, no public TGA notice has reversed that decision, and no BPC-157 product is listed on the ARTG [2]. There is no legal pathway to obtain BPC-157 as a prescribed, pharmacist-compounded medicine — even with a script from an AHPRA-registered doctor — because the TGA has explicitly removed it from the compounding pathway.

The prohibition is narrower than full scheduling. BPC-157 has no Poisons Standard entry granting it Schedule 4 status; it is regulated as an unapproved therapeutic good whenever promoted or supplied for human therapeutic use because the TGA's definition of a therapeutic good is based on representation and intended use [2][4]. Vendors offering BPC-157 under a "research use only" or "not for human consumption" label rely on the position that in-vitro and laboratory research falls outside therapeutic goods law. The TGA's 2024 advertising guidance is clear that disclaimers do not override therapeutic characterisation if the product is presented or reasonably expected to be used in people [10].

Before purchasing for any purpose, verify current status at tga.gov.au. Format and concentration details for laboratory stock, including the Body Pharm BPC-157 5 mg vial, sit on the broader BPC-157 product page.

What Does 'Research Use Only' Actually Mean in Australia?

"Research use only" is not a legal exemption under Australian therapeutic goods law. The TGA assesses the substance and the intent of supply, not the disclaimer printed on the vial [2]. If a peptide is promoted, packaged, or reasonably expected to be used for a therapeutic purpose in people, it is captured as a therapeutic good regardless of "not for human consumption" wording because the TGA's definition turns on representation and intended use [2][3].

Legitimate research use in Australia has identifiable features: a qualified investigator at a recognised institution, a documented protocol, Human Research Ethics Committee (HREC) or Animal Ethics Committee approval where applicable, and procurement through accounts tied to that institution or its approved suppliers. These features demonstrate that the supply is genuinely for research and not for human therapeutic use. Bulk peptides ordered to a residential address, paid for personally, and stored alongside syringes and bacteriostatic water do not resemble institutional research. A disclaimer does not change that characterisation [2][3].

How the TGA and ACCC view the label

The TGA's 2024 advertising guidance is explicit that misleading disclaimers do not avoid classification as a therapeutic good [2]. Compliance activity through 2024–2025 against unapproved performance and image-enhancing drugs sold online has targeted vendors using exactly this labelling strategy. The TGA's enforcement is based on actual supply and promotion, not on the vendor's stated intent [3][12]. The ACCC's parallel concern sits under the Australian Consumer Law: representations that imply safety, quality, or regulatory standing the product does not have can be misleading conduct, irrespective of a research disclaimer, because the ACCC regulates consumer representations based on what a reasonable consumer would understand [15].

The telehealth "add to cart" problem

Online clinics that let buyers add prescription peptides such as semaglutide or tirzepatide to a cart before any clinical assessment sit in the same risk zone. Schedule 4 medicines cannot be advertised directly to consumers because the Therapeutic Goods Advertising Code restricts promotion of prescription-only medicines. AHPRA's 2024 telehealth guidance discourages purely questionnaire-based prescribing for higher-risk medicines because it removes the clinical assessment that justifies prescription status [18][19]. A storefront flow that resembles e-commerce, followed by a perfunctory script, does not convert an unapproved supply into a compliant one.

Practical takeaway

If you are buying for genuine in-vitro or preclinical work, document the protocol, the institutional approval, and the chain of custody before you order — these documents demonstrate legitimate research use. This guide is not legal advice; where your situation is unclear, seek independent legal advice.

How to Evaluate a Peptide Supplier in Australia: The COA Checklist

A legitimate Australian peptide supplier should provide a batch-specific Certificate of Analysis from a named third-party laboratory — batch-level documentation is the only way to verify that the product you receive matches the specification you ordered. JCSG.org requests batch-specific COAs from Body Pharm for all products in the range; if you need a COA for your order, contact us through the site.

The checklist below lets you assess any supplier in under ten minutes:

The eight-point supplier checklist

1. Certificate of Analysis (COA), per batch. A usable COA names the compound, the CAS (Chemical Abstracts Service) number where one exists, the batch or lot number, the synthesis or release date, the analytical method, and the measured purity. Research-grade peptides are commonly specified at ≥95% HPLC purity in the peer-reviewed synthesis literature, with ≥98% the premium benchmark for in-vivo or pharmacology work because higher purity reduces the risk of contaminant-related variability in results [3][4]. If the vendor cannot send you the COA for the exact batch you will receive, walk away.

2. Third-party lab verification. The COA should be issued by a laboratory independent of the manufacturer, with the lab's name, address and signatory visible. Self-issued COAs on the vendor's own letterhead, with no named analyst and no instrument trace, are the single most common quality-assurance gap in the Australian research peptide market. Treat them as unverified.

3. Unique batch numbering. Every vial should carry a batch or lot number that matches the COA on file. Generic "Batch 001" labels reused across SKUs (stock keeping units), or products shipped without a printed lot number, break the chain of custody you need for any preclinical record.

4. ABN verification. Look up the trading entity on the ABN Lookup tool at abr.business.gov.au. Confirm the ABN is active, the entity name matches the invoice, and the GST (Goods and Services Tax) registration status is consistent with the prices charged. Inconsistencies signal either a shell company or deliberate obfuscation. You have no legal recourse under the Australian Consumer Law if the vendor will not name its trading entity.

5. Transparent contact details. A registered street address (not only a PO box), a working Australian phone number, and a named responsible person. Offshore drop-ship operations using only a contact form are higher risk for both quality and recourse.

6. Cold-chain and shipping documentation. Lyophilised peptides are temperature-sensitive; reconstituted peptides more so. Ask for the vendor's storage and dispatch standard operating procedure (SOP), whether ice packs or gel packs are used, and the expected transit window. Silence on this is a quality signal in itself.

7. Returns and quality guarantee policy. A written policy covering damaged shipments, failed COA verification on independent retest, and replacement timelines. "All sales final" on biologics is a red flag.

8. No therapeutic claims on product pages. Pages for Schedule 4 compounds such as semaglutide or tirzepatide should not promote weight-loss outcomes, dosing protocols, or human-use instructions to the public, because direct-to-consumer promotion of prescription-only medicines breaches the Therapeutic Goods Advertising Code. A vendor willing to ignore that rule is signalling how it treats every other rule [11][16].

Red Flags: What a Weak COA Looks Like

A weak COA is one that cannot be tied back to a specific batch, a specific compound, and a named third-party laboratory. If any of those three anchors is missing, treat the document as marketing collateral rather than analytical evidence.

Common red flags:

• No named third-party laboratory, or only an in-house "QC department" signature
• A purity figure (e.g. "99%") with no testing method stated — analytical HPLC, mass spectrometry (MS), and water/acetate content should each be reported
• Missing batch number, synthesis date, or expiry; or a COA date that does not match the batch printed on the vial in hand
• A generic PDF template where the compound name, sequence, and molecular weight look pasted in, with no compound-specific chromatogram or mass spectrum
• Purity below the 95% HPLC threshold accepted as the working minimum for research-grade peptides in 2023–2025 synthesis literature [18][19]
• Supplier cannot produce the COA on request, or will only show a thumbnail image

A strong COA names the lab, shows the chromatogram, ties the result to a batch number, and travels with the vial — whether that vial is a research lyophilate or a Schedule 4 semaglutide prefilled pen or tirzepatide 30-dose pen dispensed on prescription.

Peptide Formats Compared: Vials vs. Prefilled Pens in 2026

Two formats dominate the Body Pharm range: lyophilised (freeze-dried) vials that the end user reconstitutes with bacteriostatic water, and prefilled pens with pre-measured doses set at the device. The choice depends on handling tolerance, protocol length, and how much reconstitution variability you can accept across a multi-week study.

Lyophilised vials are the older format and remain the most cost-effective per milligram because they require minimal manufacturing complexity. They demand correct reconstitution: matching diluent volume to the target concentration, swirling rather than shaking, drawing accurate insulin-syringe volumes, and storing the reconstituted vial at 2–8 °C with a working life typically capped at 28 days once water touches the powder. Each step introduces user error that can drift the final dose. A 5 mg BPC-157 vial reconstituted to 2 mL gives 2.5 mg/mL; miscalculate the diluent and the dose is wrong from the first draw.

Prefilled pens remove most of that arithmetic. The cartridge ships pre-mixed (or with an integrated dual-chamber mechanism), the dial sets the dose in fixed increments, and the device is engineered for repeat dose consistency across the cartridge's labelled life. That matters most in longitudinal protocols, where cumulative reconstitution error compounds over time. A Retatrutide 64-dose pen is built for studies running 12 weeks or longer, where 64 sequential reconstitutions from vials would introduce uncontrolled variability. A BPC-157 & TB500 32-dose pen suits shorter combination protocols because the fixed-dose format reduces the arithmetic burden. Schedule 4 prescription products including the semaglutide prefilled pen and tirzepatide 30-dose and 60-dose pens ship exclusively in pen format because dose consistency is a regulatory expectation for human-use medicines.

Cold chain applies to both. Unopened lyophilates tolerate brief room-temperature transit because the lyophilised state is stable; pens generally require 2–8 °C throughout, with limited in-use room-temperature windows specified by the manufacturer.

Format	Reconstitution required	Dose consistency	Best for	Body Pharm products on JCSG.org
Lyophilised vial	Yes (bacteriostatic water)	Operator-dependent	Short protocols, low-dose research, cost-sensitive work	BPC-157 5 mg vial
Prefilled pen	No	Device-controlled	12+ week protocols, Schedule 4 prescription products	Retatrutide 64-dose, semaglutide pen, tirzepatide pens

The JCSG Australia Range: Body Pharm Peptides Available in 2026

The current range covers eleven research peptides across five application areas, with formats spanning lyophilised vials, prefilled pens, and combination products. Schedule 4 status, ARTG registration, and clinical development stage vary by compound, so each group below flags the relevant compliance context before listing the products.

All products listed below are for research use only and not for human therapeutic use.

Metabolic and GLP-1 pathway research

Incretin-receptor agonists are the most heavily regulated peptides in the range because they have demonstrated clinical efficacy and are subject to full pharmaceutical regulation. Semaglutide (GLP-1 agonist) and tirzepatide (dual GIP/GLP-1 agonist) are both Schedule 4 prescription-only medicines in Australia, supplied exclusively as prefilled pens (tirzepatide in 30-dose and 60-dose configurations) because the TGA requires prescription medicines to be supplied in a format that ensures dose consistency and proper administration [8][9]. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical development internationally; it is not TGA-approved for human use as of mid-2026 and does not appear on the ARTG [19][20]. The Retatrutide 64-dose pen is supplied for research purposes only.

Growth hormone axis research

This group covers GHRH analogues and GH (growth hormone) secretagogues used in preclinical endocrinology work. CJC-1295 with DAC (extended half-life via albumin binding) and CJC-1295 paired with Ipamorelin (a selective ghrelin receptor agonist) are supplied as lyophilised vials because they are not ARTG-listed. Tesamorelin is a stabilised GHRH(1-44) analogue with published clinical data on visceral adipose tissue reduction in HIV-associated lipodystrophy populations; it is treated as a prescription-only peptide when supplied as a medicine in Australia, with no ARTG-listed generic [9][11]. None of the CJC or ipamorelin products hold ARTG registration for human therapeutic use.

Tissue repair and regenerative research

BPC-157, TB500 (thymosin beta-4 fragment), and the BPC-157 & TB500 32-dose combination pen are supplied as research peptides only. BPC-157 has been subject to a TGA prohibition on compounding for human use since February 2024, and that prohibition remains in force in 2026 [17][18]. TB500 and GHK-Cu (a tripeptide-copper complex studied in extracellular matrix and fibroblast research) are not listed on the ARTG as injectable therapeutic goods.

Mitochondrial and longevity research

NAD+ (nicotinamide adenine dinucleotide) and MOTS-C (a mitochondrial-derived peptide) are supplied for in-vitro and preclinical longevity research. Injectable NAD+ is handled as a prescription or practitioner-only ingredient when used in ARTG-listed products, while bulk research-grade material is an unapproved therapeutic good if promoted for human use [11][12]. MOTS-C has no ARTG entry.

Melanocortin pathway research

Melanotan II is a synthetic melanocortin receptor agonist studied for pigmentation and appetite signalling pathways. It has been the subject of repeated TGA safety advisories since the 2010s and is treated as an unauthorised therapeutic good when supplied for human use. It is available in the range strictly as a research peptide.

Shipping, Storage, and Handling: What Australian Buyers Need to Know

Peptide stability depends on temperature control from dispatch through to long-term storage. Improper handling is one of the most common causes of compromised research results — peptides are proteins, and proteins denature when exposed to heat, moisture, or light. JCSG.org dispatches Body Pharm peptides domestically within Australia, reducing the cold-chain risk inherent in cross-border parcels held at customs and eliminating the Australian Border Force inspection risk associated with international peptide imports.

Domestic dispatch vs. international import

Domestic dispatch avoids the two main failure points of international orders: prolonged transit at ambient temperature and Australian Border Force inspection of parcels containing unapproved therapeutic goods. Both factors degrade the product or result in seizure. International peptide shipments routinely face seizure and referral to the TGA where the product is captured by therapeutic goods law, regardless of "research use only" wording on the label [11][13]. Lyophilised vials are generally robust to brief ambient excursions during shipping because the lyophilised state is stable. Reconstituted or liquid-formulation products (including the semaglutide prefilled pen and the tirzepatide 30-dose and 60-dose pens) require cold-chain handling and are not suitable for slow international post.

Storage on receipt

Lyophilised peptides are typically stored at −20 °C for long-term stability and at 2–8 °C for short-term use over days to a few weeks, consistent with standard commercial peptide supplier specifications [19]. Once reconstituted in bacteriostatic water or saline, the usable window shortens substantially because the aqueous environment accelerates peptide degradation. Most suppliers recommend refrigerated storage at 2–8 °C and use within 14–28 days depending on the specific sequence. Sensitive peptides such as BPC-157 and GHK-Cu degrade faster than more stable analogues because some sequences are more susceptible to hydrolysis and oxidation [19].

Packaging integrity checks

On arrival, inspect vials for cracked stoppers, discoloured powder, visible moisture inside the vial, or a missing tamper seal. Lyophilised material should appear as a white, uniform cake or powder. Any deviation — or an ice pack that has fully thawed to ambient on a temperature-sensitive product — is grounds to contact us before use. Request batch documentation against the COA to verify that the product you received matches the specification on file.

Frequently Asked Questions: Buying Peptides in Australia